TY - GEN
T1 - Entrepreneurial Orientation on Clinical Development in Pharmaceutical Industry
T2 - 2022 Portland International Conference on Management of Engineering and Technology, PICMET 2022
AU - Matsuda, Dai
AU - Yoshioka-Kobayashi, Tohru
AU - Maki, Kanetaka M.
N1 - Funding Information:
This study was documented in a project of Waseda Research Institute of Business and Finance and graduation paper for Graduate School of Business, Waseda University. I appreciate my colleagues of Science, Technology and Entrepreneurship Zemi for their advice.
Publisher Copyright:
© 2022 PICMET.
PY - 2022
Y1 - 2022
N2 - Success in pharmaceutical clinical development requires organizational management capabilities. 'Entrepreneurial Orientation (EO)' is a strategic construct that reflects the extent to which firms are innovative, proactive, and risk taking in their behavior and management philosophies. This study elucidates how EO influences clinical development in pharmaceutical firms. Panel-data analysis was conducted using a fixed-effect model. The panel data consists of 29 global pharmaceutical firms focusing on novel drug development for 14 years from 2004 to 2017. Accumulative numbers of novel drug approval in the United States are set as a dependent variable. Independent variables are EO components, stock beta value, and annual turnover. The EO consists of three entrepreneurial factors of innovativeness (R&D expense per sales), proactiveness (R&D expense per EBITDA), and risk taking (Stock volatility). The study results indicate that innovativeness and risk taking showed a significant positive association with an increase in the cumulative number of new product approvals. Risk taking also showed positive association both when excluding bio-tech firms and in biotech firms, but proactiveness was negative only when excluding bio-tech firms. As a result, the study showed that EO impacts novel drug approval in the pharmaceutical industry. Traditional large firm should take risks in separate small organization.
AB - Success in pharmaceutical clinical development requires organizational management capabilities. 'Entrepreneurial Orientation (EO)' is a strategic construct that reflects the extent to which firms are innovative, proactive, and risk taking in their behavior and management philosophies. This study elucidates how EO influences clinical development in pharmaceutical firms. Panel-data analysis was conducted using a fixed-effect model. The panel data consists of 29 global pharmaceutical firms focusing on novel drug development for 14 years from 2004 to 2017. Accumulative numbers of novel drug approval in the United States are set as a dependent variable. Independent variables are EO components, stock beta value, and annual turnover. The EO consists of three entrepreneurial factors of innovativeness (R&D expense per sales), proactiveness (R&D expense per EBITDA), and risk taking (Stock volatility). The study results indicate that innovativeness and risk taking showed a significant positive association with an increase in the cumulative number of new product approvals. Risk taking also showed positive association both when excluding bio-tech firms and in biotech firms, but proactiveness was negative only when excluding bio-tech firms. As a result, the study showed that EO impacts novel drug approval in the pharmaceutical industry. Traditional large firm should take risks in separate small organization.
UR - http://www.scopus.com/inward/record.url?scp=85139171317&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85139171317&partnerID=8YFLogxK
U2 - 10.23919/PICMET53225.2022.9882621
DO - 10.23919/PICMET53225.2022.9882621
M3 - Conference contribution
AN - SCOPUS:85139171317
T3 - PICMET 2022 - Portland International Conference on Management of Engineering and Technology: Technology Management and Leadership in Digital Transformation - Looking Ahead to Post-COVID Era, Proceedings
BT - PICMET 2022 - Portland International Conference on Management of Engineering and Technology
A2 - Kocaoglu, Dundar F.
A2 - Anderson, Timothy R.
A2 - Kozanoglu, Dilek Cetindamar
A2 - Niwa, Kiyoshi
A2 - Steenhuis, Harm-Jan
PB - Institute of Electrical and Electronics Engineers Inc.
Y2 - 7 August 2022 through 11 August 2022
ER -